Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Shot 5%-Plus Higher on Thursday

By Eric Volkman - May 20, 2021 at 4:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two news items on the opposite side of the world pushed the shares up on the day.

What happened

Moderna (MRNA -5.06%) was a strong performer Thursday, rising to close 5.1% higher. Two pieces of good news from across the Pacific Ocean formed a bullish wave lifting the shares skyward.

So what

The first, and more direct, of the two came from Japan's Health Ministry. An expert panel at the ministry formally recommended that the government approve Moderna's mRNA-1273 coronavirus vaccine for use in the populous Asian nation. Health Minister Norihisa Tamura said that such a nod could come on Friday -- a likely scenario given there's little time to waste in what's still a significant global healthcare crisis.

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

Moderna's approval in Japan now seems like a foregone conclusion. Not only has Moderna already imported doses for use in the country, but mRNA-1273 is authorized for emergency use in the U.S. and the European Union. Particularly in the U.S., it is a go-to choice for mass inoculation.

Meanwhile, fellow coronavirus vaccine developer BioNTech's CEO Ugur Sahin said that BNT162b2 -- the jab it co-developed with Pfizer -- is likely to prove 70% to 75% effective in blocking infections of the feared coronavirus variant recently detected in India.

The BioNTech/Pfizer shot is similar to Moderna's as both harness messenger RNA in the fight against the coronavirus.

Now what

In countries like India, the coronavirus remains a major threat, and in countries like Japan it's a problem still short of solutions. Today was a reminder that the Moderna vaccine is still a potent and readily available solution.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.58 (-1.40%) $0.69
BioNTech SE Stock Quote
BioNTech SE
BNTX
$147.61 (-2.91%) $-4.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.